Risk factors for non-compliance to treatment with highly effective antiretroviral therapy by Colombrini, Maria Rosa Ceccato et al.
Rev Esc Enferm USP
2008; 42(3):487-92.
 www.ee.usp.br/reeusp/ 487
Risk factors for non-compliance to treatment
with highly effective antiretroviral therapy
Colombrini MRC, Dela Coleta MF, Lopes MHBM
FATORES DE RISCO PARA A NÃO ADESÃO AO TRATAMENTO COM TERAPIA
ANTIRETROVIRAL ALTAMENTE EFICAZ
FACTORES DE RIESGO PARA LA NO-ADHERENCIA  AL TRATAMIENTO CON TERAPIA
ANTI-RETROVIRAL ALTAMENTE EFICIENTE
Maria Rosa Ceccato Colombrini1, Marília Ferreira Della Coleta2,
Maria Helena Baena de Moraes Lopes3
RESUMEN
Objetivo del estudio: medir la prevalencia
por falta de seguimiento al tratamiento anti-
retroviral altamente eficaz (HAART) en pa-
cientes con SIDA; identificar si algunos fac-
tores relacionados en la bibliografía se en-
cuentran asociados con la falta de segui-
miento; establecer el valor preditivo de los
factores asociados con la falta de segui-
miento al HAART. Para lo cual fue realizado
un estudio analitico de prevalencia (N=60),
considerándose los tres días anteriores a la
entrevista, donde aquellos pacientes con in-
gesta del 95% o más del total de comprimi-
dos prescritos por día eran clasificados como
seguidores del tratamiento. El seguimiento
fue de 73,3%. El análisis de regresion logísti-
ca multi-variable mostró que sujetos de raza
negra presentaron 6,48 veces mayor riesgo
de no continuar con el tratamiento; aquellos
individuos sin efectos colaterales tuvieron
un riesgo 7,6 veces mayor, asimismo, cada
comprimido ingerido produjo un riesgo de
1,12. El seguimiento observado fue mayor
al encontrado en la bibliografía existente.
Los factores socio-demográficos y culturales
pueden influir en el seguimiento de la HAART.
DESCRIPTORES
Síndrome de inmunodeficiencia adquirida.
Terapia antirretroviral altamente activa.
Negativa del paciente al tratamiento.
Factores de riesgo.
ABSTRACT
The purpose of the study was: to measure the
prevalence of non-compliance to highly ac-
tive antiretroviral therapy (HAART) by AIDS
patients; to identify whether some of the
factors listed in health literature were as-
sociated with non-compliance; to establish
the predictive values of non-compliance to
HAART-related factors. An analytic preva-
lence study (N=60) was performed, in which
the three days prior to the interview were
considered. Those classified as compliant
were the patients who ingested 95% or over
of the total amount of pills prescribed a day.
Compliance appeared as 73.3%. The multi-
variate logistic regression analysis indicat-
ed that the black subjects presented 6.48
times higher risk for non-compliance. Those
who did not present side effects showed
7.6 times higher risk, and a risk of 1.12 for
each pill taken. The compliance observed
in the study proved to be higher than in lit-
erature. The sociodemographic and cultural
factors may interfere in the compliance with
HAART.
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RESUMO
O estudo objetivou: mensurar a prevalên-
cia de não-adesão à terapia anti-retroviral
altamente eficaz (HAART) em pacientes com
AIDS; identificar se alguns fatores relaciona-
dos na literatura estavam associados com a
não-adesão; estabelecer o valor preditivo dos
fatores associados à não-adesão à HAART. Foi
realizado um estudo analítico de prevalên-
cia (N=60). Foram considerados os três dias
anteriores à entrevista e os pacientes clas-
sificados como aderentes quando ingeriam
95% ou mais do total de comprimidos pres-
critos por dia. A adesão foi de 73,3%. A análi-
se de regressão logística multivariada indi-
cou que indivíduos da raça negra apresen-
taram 6,48 vezes mais risco de não-adesão;
aqueles que apresentaram ausência de efei-
to colateral tiveram um risco 7,6 vezes maior,
e a cada comprimido ingerido o risco foi de
1,12. A adesão observada foi maior que a en-
contrada na literatura. Os fatores sociode-
mográficos e culturais podem interferir na
adesão à HAART.
DESCRITORES
Síndrome de imunodeficiência adquirida.
Terapia anti-retroviral de alta atividade.
Recusa do paciente ao tratamento.
Fatores de risco.
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INTRODUCTION
Since ancient times, when humans began to use medica-
tion, there has been concern regarding compliance to treat-
ments. The importance of studying compliance to treatment
of the Acquired Immunodeficiency Syndrome (AIDS) is mainly
related to the severe consequences that this disease implies
to the individuals, families and communities. Furthermore,
the literature has shown that there is relation among viral
resistance, therapeutic failure and low compliance(1).
Estimates show that 38.6 million (33.4 – 46 million) people
worldwide were living with the Human Immunodeficiency
Virus (HIV) in 2005; 4.1 million (3.4 – 6.2 million)  individuals
have recently been infected by the HIV and 2.8 million (2.4 –
3.3 million) lost their lives because of AIDS(2). In Brazil, since
the identification of the first case of AIDS, in 1980, until June
2005, 371.000 cases of the disease have been reported (3).
The treatment results with a Highly Active Antiretroviral
Therapy (HAART) show the effectiveness of the therapy and,
consequently, prove the importance that the public health
service has to attain better results. Studies show
that non-compliance occurs to a certain extent
both in poor and rich countries. The average
rate is 50%(4-5). Researchers have strived to
measure compliance by means of direct
questions, indirect estimates, manual or
electronic counting, biological markers or
metabolite dosage.(6-7).
The literature has shown several predic-
tive factors for non-compliance with HAART
treatment that may be grouped in factors re-
lated to the following items: person in treat-
ment; disease; healthcare service and social
support(5,7-8).
These indicators show that some interventions are re-
quired so as compliance is constructed in a continuous
process between professionals and clients. The latter should
comply with treatment, understand and commit to perform
the guidance dispensed(9).
It should be taken into account that in order to favor
compliance to treatment among individuals with the HIV
virus, it is fundamental that the health team knows the
factors that may interfere in compliance. It is imperative
that the clientele’s specificities are recognized(10). Thus, this
study’s goal was to identify the factors that could predict
non-compliance in a more appropriate approach regarding
individuals with HIV at a Day Bed Unit (DB) of a teaching
hospital in the countryside of the State of São Paulo.
OBJECTIVES
This study had the purposes of measuring the prevalence
of non-compliance to HAART in the sampling; identifying
whether some factors related to individuals under treatment,
healthcare service and social support were associated with
non-compliance to HAART; and establishing the predictive
value of factors associated with non-compliance to HAART.
METHOD
This was an analytical study of prevalence(11). Data were
collected in a private place at the referred BD Unit during
the month of March in 2002.
The patients were contacted at the study place and in-
formed about its objectives and the interview procedures.
The interview data were registered in the questionnaire
specifically created for the study.
The term of consent was thoroughly read with the pa-
tients so as to obtain authorization to proceed with the
research. Their questions were answered and their pri-
vacy was ensured. The research was approved by the Eth-
ics Committee in Research of the Institution (no. 326/2001).
The sample was composed by HIV-positive patients,
registered at the BD Unit and participants of
the bed-day program in the month of March
2002, with 79 patients.
In order to be included in the study, the
individual had to be able to answer the ques-
tions directly and should be using antiretro-
virals for at least a week, at home. The exclud-
ed individuals were inmates who were likely
to have difficulty in following the therapeu-
tics prescribed due to the penitentiary con-
ditions. Furthermore, the presence of police
officers at the moment of the interview could
inhibit the answers to the questions.  Patients
who were living in support houses were also
excluded. In these places, they were not responsible for
their own drug treatment. The presence of a nursing pro-
fessional to administer medication was compulsory.
To collect data, a form was elaborated with questions
regarding variables to characterize the sampling, independ-
ent variables (factors associated with non-compliance) and
dependent variables (non-compliance with the treatment).
Prior to beginning data collection, the complete in-
strument was pre-tested in order to check its adequacy, at
the ambulatory of infectious diseases in the month of Febru-
ary/2002, with eight patients (four males and four females).
To identify the factors associated with non-compliance,
a literature review was performed in the Medline and Lilacs
databases, with the two uniterms: compliance and
adherence. As AIDS is a recent disease, so are the studies
on specific compliance to highly effective antiretroviral
therapy. Hence, in this review, classic studies of chronic
diseases in general were excluded. They have been used
by the AIDS-related literature and dated back to the
beginning of highly effective antiretroviral therapy.
(...) that some
interventions are
required so as
compliance is
constructed in a
continuous process
between professionals
and clients. The latter
should comply with
treatment...
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Thus, based on the literature, the following factors
(independent variables) were investigated: ethnicity; age;
gender; sexual orientation; educational background, social
isolation; absence of therapeutic advantage; need of periodic
control; length of treatment (including the number of doses,
number of medication, side effects and lifestyle changes);
access to service; convenience to schedule consultations and
procedures; social support; suitable information; feeling well;
feeling bad; drug use; psychiatric disorder or syndrome;
evaluation of the laboratorial results; disease gravity and
perception of control over their own health(4-8,12-13).
Non-compliance was considered as a dependent vari-
able, which was defined with the aid of the patients’ re-
ports that showed how many pills they had taken per day, in
the past three days. The pill intake was verified. The indi-
viduals who reported taking less than 95% of the prescribed
medication were considered non-compliant(8,12). There are
several methods to evaluate non-compliance and all of them
contain important limitations. However, the direct ques-
tioning method has often been used so as not to overestimate
compliance. When appropriately used, it turns out to be a
good compliance indicator(13). The self-report was the cho-
sen method for this study. It is easily applied and incorpo-
rated to the Unit routine, with low operational cost.
The data were inserted in a databank by using the
software EPI-INFO. For the statistical analysis, The SAS
System software for Windows(14) was used.
To verify the association among the category variables
and the dependent variable, the chi-square test was used, or
Fisher’s exact test, when indicated.  The Mann-Whitney test
was used to compare the continuous variables among the
individuals who were compliant and non-compliant with
the treatment.
Logistic regression analysis with a logit model and
Stepwise criterion to select the most significant variables
was used to analyze the variable influence over the profile
of the compliant and non-compliant individuals. Initially,
there were univariate analyses and afterwards, the most
significant variables were selected by the multivariate anal-
ysis. The significance level for the statistical tests was 5%,
that is, p<0.05.
RESULTS
In the month of March/2002, there were 79 patients
registered in the BD Program. Of them, 17 (21.5%) did not
meet the inclusion criteria and two (2.5%) interrupted the
interview because they could not answer the questions.
Therefore, 60 (76%) patients were interviewed.
The study showed a prevalence of 16 (26.7%) non-com-
pliant patients and 44 (73.3%) compliant patients.
There was predominance of whites (39 or 65%) and the
age group of 30-39 years (30 or 50%). The youngest was 21
years old and the oldest was 66 years old, and the average
age was 37.49 (SD= 9.3), and median of 36.78.
The sampling showed a male/female ratio of 2:1 and 44
(73.3%) reported being homosexuals. Regarding education-
al background, the average was 7.25 (SD= 4.3) years of study,
ranging from 0 to 20 years of study, with 6.5 years on aver-
age. No interviewed individual was a student.
Of the 60 patients who participated in this study, 26 (43.3%)
identified some social isolation. In addition, 13 (50%) re-
garded this situation as a consequence of their becoming
distant from their families, friends and/or partners.
The return to the BD happened monthly for 30 (50%) par-
ticipants. Of the 19 (31.7%) patients who had some diffi-
culty in accessing the Unit, eight mentioned the lack of trans-
portation as the main hindrance. The remaining patients cited
the fact that they depended on other people, financial dif-
ficulties and time expenditure.  For 46 (76.7%) patients, the
consultation scheduling was in accordance with their daily
activities.
The time span of treatment was 4.22 years (SD= 3.46),
with the shortest time span being 1 month and the longest
12.22 years. The median was 3.22 years. The time interval
between HIV infection and the beginning of treatment was
1.37 years (SD= 3.54), varying from 0 to 15 years. The treat-
ment was initiated at the moment of the diagnosis by 47
patients (78.3%).
For 27 (45%) patients, the frequency of the antiretro-
viral pills was twice a day. The prescribed therapeutic frame-
work varied from five to 25 pills a day (average = 11.48; SD
= 5.25; median = 11 pills).
Of the interviewed individuals, 45 (75%) were under pro-
phylactic or therapeutic treatment associated with other dis-
eases (tuberculosis, pneumocystosis, toxoplasmosis, cryp-
tococcosis) and, besides antiretroviral medication, they had
an average intake of six (SD= 3.8) pills a day, varying from
one to 16 pills (median=5). When the antiretrovirals and the
medication for other diseases were added, the average val-
ue obtained was 15.9 (SD = 6.9) pills a day, varying from a
minimum of 5 to a maximum of 33 pills (median=16).
In the opinion of 48 (80%) interviewed individuals, there
were improvements with the received treatment. Thirty-
eight of them (63.3%) reported not feeling side effects after
taking the antiretroviral pills. Fifty (83.3%) reported that,
when they were feeling better, they did not discontinue the
treatment. Likewise, 47 (78.3%) did not interrupt the treat-
ment. Not even when they felt ill.
For 43 (71.7%) patients, there were some changes in the
life routine in function of treatment and 46 (76.7%) did not
see difficulty in carrying out the treatment.
Social support was present for 29 (48.3%) interviewed
patients. It was characterized in this study as the presence
of solidarity or collaboration from other people, financial
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support from official institutions or charities, and provi-
sion of food.
When questioned about the information provided to the
healthcare team regarding disease, treatment, care required
during social and sexual relationships, among others, 47
(78.3%) considered that they were enough to clarify aspects
related to the disease, treatment and required care. For 13
(21.7%) patients, the information was partially sufficient.
It was found that in the past, 38 (63.3%) patients con-
sumed alcohol and/or drugs (inhalatory and/or intra-
venous) and acknowledged dependency.  Of them, 19 (50%)
used only alcohol, 8 (21.1%) only drugs and 11 (29%), both.
When questioned about the use of alcohol and drugs at the
moment of the interview, 10 patients answered that they
continued to use alcohol and/or drugs and acknowledged
dependency.
It was verified that 34 (56.7%) improved their laborato-
rial results after the classification of the last values of viral
load and CD4+. It is worth mentioning that, although 12
individuals had undetectable viral load, 51 (85%) were
classified as C3, that is, they showed defining conditions
of AIDS and CD4+ <200 T-lymphocytes/mL, according to
the disease classification attributed by the Center for
Disease Control (Centro de Controle de Doenças – CDC)(15).
The univariate analysis showed that the proportion of
non-compliant individuals was higher among the blacks
(p=0.012). The age of the compliant group was significantly
lower (p=0.0476) when compared with the age of the non-
compliant, although the p-value was near the 5% limit. The
absence of side effects was associated with non-compliance
(p=0.019) and the variable result of the total number of
prescribed pills a day was seen to be significant (p=0.0402).
Non-compliant individuals showed lower educational
background than those who were compliant (p=0.0273). There
were associations between educational background that were
equal or lower than six years and non-compliance (p=0.02).
The findings showed that the variables ethnicity (black),
age (40 to 49 years), educational background (£ 6 years),
side effects (absence) and the total number of prescribed
pills were associated with non-compliance to treatment.
Further comparisons were carried out, seeking to identify
whether the ethnicity factor was associated with some socio-
economic characteristics, namely family income, living con-
ditions, occupation and type of work and educational back-
ground. There were only associations between black eth-
nicity and educational background lower or equal to six
years (p=0.010).
Through univariate logistic regression analysis, there
were associations between non-compliance and the vari-
ables: age (11.0 times more risks for the 40-49 year-olds),
side effects (5.8 times more risk for absence of effects),
ethnicity (5.0 times more risk for black ethnicity, educa-
tional background (4.3 times more risk for £6 year-olds).
The number of pills prescribed a day variable was not sig-
nificant when the results were analyzed separately (number
of antiretroviral pills and others). However, by adding the
total number of pills, the result showed a trend (p=0.0546)
with 1.09 more risk for non-compliance.
Following the univaried analysis, a multivariate logis-
tic regression analysis was performed, (Table 1) with Step-
wise selection. The following variables were associated with
non-compliance: ethnicity, side effects and total number of
pills prescribed a day. The black ethnicity showed 6.48
more risk for non-compliance than whites or Asians; those
who reported the absence of side effects had 7.6 more risk
for non-compliance, and each pill increased the risk in 12%
– that is, the risk was 1.12. It can also be stated that the risk
was 3.2 (1.1 – 9.7) for every 10 pills.
Table 1 – Multivariate logistic regression analysis, with Stepwise, of factors associated with non-compliance –
Campinas – 2002
Note: BD Unit (N=60)
OR (“Odds Ratio”) = Odds ratio for non-compliance (44 compliant and 16 non-compliant). TI 95% OR = Trust Interval of 95% for the Odds Ratio.
* Comparison level/reference level   ** Comparison level could not be determined
Variable Comparisonlevel* p O.R. TI 95% O.R.
Ethnicity Black/White or Asian 0.0110 6.48 1.54 – 27.36
Absence of side effects No/Yes 0.0229 7.60 1.32 – 43.63
Total number of prescribed pills a day Each pill** 0.0397 1.12 1.01 – 1.26
DISCUSSION
Non-compliance in this study was 26.7%. It is a result
that is lower than what is shown in the literature(4-6). This
may have occurred due to several factors, among them: data
collection was performed in a single interview, without client
accompanying; the sampling was homogenous; there may
have been the involvement of a multiprofessional team,
with real understanding of their role in assisting the patient
to construct compliance on a daily basis, and, therefore,
improve antiretroviral intake.
The multivariate logistic regression analysis, with
Stepwise selection, demonstrated that only some variables
maintained association with non-compliance: ethnicity,
side effects and the total number of pills prescribed a day.
Black individuals showed 6.48 times more risk of non-
compliance than white or Asian individuals.
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Researchers verified that the non-Caucasian patients
were significantly more non-compliant than Caucasian
patients(16). In another study, the authors showed that there
was a relative risk of 1.7 regarding non-white ethnicity (8).
A study on tuberculosis evidenced that no sociodemogra-
phic variable was consistent to measure non-compliance to
treatment, except for complexion. However, there was no spec-
ification of the risk it represented(17).
The absence of side effects increased 7.6 times the risk for
non-compliance. In contrast, other authors argue that com-
pliance decreases as side effects increase(6-7).
The literature offers data that may explain such result.
Two studies evidenced that HIV patients were more likely
to bear the side effects than less severe chronic diseases
such as hypertension or diabetes. Negative attitudes re-
garding medication and diseases may interfere in the pa-
tients’ compliance. The perception of how treatment influ-
ences the disease outcomes would be associated with
compliance(8,18).
A study carried out in Pelotas, RS, about compliance with
tuberculosis treatment evidenced that the drug effects and
treatment reactions involve equally important questions for
compliance. The treatment and cure expectations, motiva-
tion to maintain health, personal advantages in complying
with the therapeutic and other therapeutic benefits outline
some behaviors(17). The role of culture in popular disease
conceptions should not be disregarded. It has been largely
discussed, contrary to the positivist view. A popular
conception of AIDS medications, the antiretrovirals, causing
side effects, is likely to still exist. This reinforces the belief
that in order to cure, they ought to show such effects. How-
ever, as the study was cross-sectional, it was not possible to
evaluate whether the absence of side effects variable was
antecedent or subsequent to non-compliance. That is, non-
compliant individuals may have shown lower side effects
because they either did not take the medication or as did
not show these effects, they discontinued the treatment for
considering it ineffective. Thus, longitudinal studies are
recommended to clarify the association found.
Another component of the treatment complexity that
showed significant results was the total number of pills
prescribed a day. The results show that for each pill, the risk
for non-compliance increased by 1.12 (12%) and it was 3.2
times every 10 pills. Researchers reported that non-compli-
ance increases as the number of prescribed pills increases.
Nevertheless, the risk was not evaluated in their works. There
was direct association between low compliance and regime
complexity (number of different medications) because they
interfere in the daily routine of patients(19-20).
A research carried out in the city of Campinas, SP, with
patients under antiretroviral treatment showed that the
most frequent mistakes were related to the combined use
of drugs. The drugs most associated with mistakes were
Didadosina and Indinavir(19).
CONCLUSIONS AND
CONCLUDING REMARKS
In the present study, ethnicity, side effects and total
number of prescribed pills a day were associated with
non-compliance.
In order to better understand the results found, it is
imperative to reproduce this study with larger samples
and different characteristics. The results indicate the need
of performing longitudinal studies that can also evaluate
sociocultural aspects, beliefs, etc. related to ethnicity and
antiretroviral side effects.
During the interviews, the day of the week may interfe-
re in the compliance evaluation because some patients
would not take medication on the weekends. The difficult
factor was the hours and the social commitments. They
felt embarrassed to take medication in front of people
with whom they maintained occasional contacts.
For a more precise compliance to AIDS treatment, the
pertinent literature recommends that the 95% or more of
the prescribed pills are taken. In the present study, this
rate allowed to identify differences between the group of
compliant and non-compliant individuals.
As a perspective of further researches, it is important to
amplify the studies to other assistance sites, establishing
conditions to evaluate the quality of the assistance provided,
and also the relationships of the client with the multiprofes-
sional team, so as to favor the establishment of strategies
that improve patient compliance to HAART.
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